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Mutations in the Ras family of proteins (predominantly in H-Ras) occur in approximately 40% of urothelial cell carcinoma (UCC).
However, relatively little is known about subsequent mutations/pathway alterations that allow tumour progression. Indeed,
expressing mutant H-Ras within the mouse bladder does not lead to tumour formation, unless this is expressed at high levels.
The Wnt signalling pathway is deregulated in approximately 25% of UCC, so we examined if this correlated with the activation of
MAPK signalling in human UCC and found a signiﬁcant correlation. To test the functional signiﬁcance of this association we
examinedtheimpactofcombiningRasmutation(H-Ras
Q61LorK-Ras
G12D)withanactivatingb-cateninmutationwithinthemouse
bladder using Cre-LoxP technology. Although alone, neither Ras mutation nor b-catenin activation led to UCC (within 12
months), mice carrying both mutations rapidly developed UCC. Mechanistically this was associated with reduced levels of p21
with dependence on the MAPK signalling pathway. Moreover, tumours from these mice were sensitive to MEK inhibition.
Importantly, in human UCC there was a negative correlation between levels of p-ERK and p21 suggesting that p21 accumulation
may block tumour progression following Ras mutation. Taken together these data deﬁnitively show Ras pathway activation
strongly cooperates with Wnt signalling to drive UCC in vivo.
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Urothelial cell carcinoma (UCC) of the bladder is the ﬁfth
commonest cancer in the world.
1 The majority (75%) of
these tumours are non-invasive, well-differentiated tumours
(i.e., Ta/T1) that can be controlled by transurethral resection
of the bladder wall. However, up to 70% of the patients with a
superﬁcial UCC will have recurrences after its removal, and
10–15% will progress to muscle-invasive UCC. Even in those
that do not progress, regular surveillance by cystoscopy is
required, making bladder cancer one of the most expensive
and labour-intensive cancers to treat.
A number of genetic and epigenetic alterations involved in
bladder tumourigenesis have been identiﬁed, including
activating mutations in FGFR3 and Ras family genes,
ampliﬁcation of ERBB2, and loss of the TP53, RB1 and
PTEN tumour suppressors.
2–5
H-Ras was the ﬁrst human oncogene isolated in human
UCC, being mutated most often at codon 12, 13 and 61 (ref. 6).
As well as becoming constitutively active, mutation can also
result in overexpression of the protein because of alternative
splicing of the last intron. Despite the controversy regarding
the reported mutation frequency rate recent studies indicate
that H-Ras mutation occurs in approximately in
30–40% of low-grade papillary and up to 10% of muscle-
invasive UCC.
7,8
Transgenic models have provided invaluable information
regarding the molecular mechanisms behind H-Ras activa-
tion.
9Previously publishedstudiesbytheWu labdemonstrate
that mice carrying a transgene with a H-Ras
Q61L mutation
have early-onset urothelial hyperplasia, with this hyperplasia
progressing to low-grade non-invasive papillary tumours.
Interestingly,tumourlatencydependedontransgenenumber:
in mice that had one or two copies of the H-Ras transgene
(low-copy), the tumour latency was up to 2 years. Histologi-
cally, by 3–5 months the urothelial layer has become
hyperplastic (from 3 layers to 6–7 layers). At 8 months, the
urothelium contained areas of nodular hyperplasia. By 26
months of age, 63% of mice developed superﬁcial non-
invasive UCC. These lesions remained non-invasive during
the follow-up period. In contrast, mice harbouring ‘high-copy’
numbers of the H-Ras transgene (30–48 copies) succumbed
to death by 5 months of age. The mice had evidence
of signiﬁcantly enlarged bladders and associated bladder
outﬂow obstruction (hydronephrosis and hydroureter). Again
these tumours were of a papillary non-invasive histology, with
no evidence of muscle invasion or metastases.
The fact that the bladder tumours in ‘low-copy’ mice
developed localised, superﬁcial papillarytumours with amuch
longer latency, suggests, in the absence of overexpression,
H-Ras, activation requires a secondary event, either genetic
or epigenetic, to fully induce bladder tumours.
10
Conversely few studies have looked at K-Ras mutations in
human bladder cancer, although those that have suggest a
wide variation in frequency (4–29%).
11–13 Interestingly, a
study by Vageli et al. demonstrated the K-Ras oncogene was
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Although the human data regarding Wnt pathway activation
is quite controversial,
14 it is now becoming clear that the
pathway is activated in a proportion of UCCs. As yet
segregation of Wnt pathway high tumours into the non-
invasive, papillary pathway or the muscle-invasive pathway
hasnotbeenperformed,althoughWntpathwayactivationhas
been associated with a poor prognosis and resistance to
therapy. We have previously shown that activation of the Wnt
signalling pathway in the bladder of mice alone fails to drive
UCC, however, it strongly cooperates with PTEN loss to drive
tumourigenesis.
14
p21 is downregulated in the majority of urothelial carcino-
masthatharbour p53mutation.
15,16 Similar top53, lossofp21
expression is also associated with a higher recurrence and
lower survival rates than those tumours with maintained p21
expression levels, irrespective of tumour grade and patho-
logical stage.
16 It was also noted that maintenance of p21
expression appeared to negate the effects of p53 alterations
on UCC progression.
16 Moreover, Shariat et al.
17 demon-
strated that positive p21 expression was independently
associated with lower UCC recurrence and a slower progres-
sion to carcinoma in situ (CIS) (with no muscle-invasive
disease), possibly by p53-independent modulation of p21.
Thus far there have been no functional studies to investigate
whether p21 modiﬁes UCC tumourigenesis in vivo.
Therefore, given the observation that Ras mutation is
inefﬁcient at driving bladder carcinogenesis alone in the
mouse, the aim of this study was to test whether Ras
overexpression or mutation cooperates with deregulated Wnt
signalling to promote UCC in the murine urothelium.
Results
Human UCC demonstrate correlation between Wnt and
Ras activation. In human urothelial cancer, a number of
studies have suggested Wnt signalling is important. Of
particular note is the demonstration that nuclear b-catenin is
associated with a poor prognosis, and methylation of the
inhibitors of Wnt signalling, the SRFPs, act as markers of a
bad prognosis.
18–20 Indeed the methylation of these proteins
has been suggested as a marker of invasive bladder
carcinoma.
WehavepreviouslyshownthatinhumanUCCupregulation
of the Wnt pathway (nuclear b-catenin) is associated with
activation of the PI3K–pAKT pathway (loss of PTEN/
upregulation of pAKT
Ser473). Given this strong correlation,
we wanted to investigate which other oncogenic/tumour-
suppressor pathways were associated with Wnt signal
activation.
14 Using the same tissue microarray of 80 human
bladder cases: 60 UCC (transitional cell carcinomas), and 20
benign controls (Folio Biosciences, Columbus, OH, USA) we
chose to investigate the MAPK pathway. Using the histoscore
technique, we demonstrated a signiﬁcant correlation
between upregulation of b-catenin and activation of pERK1/2
(n¼24/56, Pearson correlation coefﬁcient¼0.6769,
Po0.0001 (two-tailed), Minitab v15, Minitab Inc., PA, USA)
(Figure 1). Interestingly, these tumours appear to be a
different subset to the ones expressing high levels of p-AKT
as no correlation between levels of p-ERK and p-AKT was
observed (Pearson correlation coefﬁcient¼0.083, P¼0.45,
Minitab v15).
Ras activation alone does not lead to UCC in the
mouse. To test whether oncogenic Ras mutation would
lead to UCC, we utilised mice carrying the constitutively
active H-Ras
Q61L oncogene (‘low-copy’). These ‘low copy’
mice have two copies of the oncogenic rabbit transgene.
Although Zhang et al.
9 demonstrated tumour latency from 10
to 26 months of age; in our hands no tumours were observed
in our H-Ras
Q61L mice cohort at killing (12 months of age). As
previously published, we noticed global hyperplasia of the
12-month-old H-Ras
Q61L urothelium compared with wild type
(Figures 2a and b).
9 There was little proliferation as observed
by Ki-67 staining (Figures 2c and d). We observed
upregulation of members of the MAPK family: pERK1/2
and pMEK1/2 in comparison to wild type (Figures 2e and f, g
and h, respectively). Importantly, we noticed an upregulation
of p21 in the mutant urothelium (Figures 2i and j), without any
accompanying nuclear accumulation of p53 (data not
shown). When we investigated members of the PI3K-
pAKT-p-mTOR (pAKT
Ser473, p-mTOR and pS6K) signalling
pathways, we failed to observe upregulation in the urothelium
(Supplementary Figure 1). In terms of Wnt signalling, we
observed scattered basal cells with nuclear b-catenin and
corresponding scattered induction of the Wnt target gene
Sox9 in the basal layer (Supplementary Figure 2). The
hyperplasia was evident in the urothelia of 3-month-old
H-Ras
Q61L mice. In this 9-month period, there was no
progression to malignancy, despite the thickness of the
urothelium increasing moderately (data not shown)
suggesting that tumour-suppressor mechanisms were
stopping progression.
We also demonstrated that the UroIICRE
þK-Ras
G12D mice
do not develop cancer when aged to 18 months of age
(n¼20). These mice carry a point mutation of the K-Ras
(K-Ras
G12D) allele, therefore Cre-mediated recombination
leads to deletion of a transcriptional termination sequence
(Lox-Stop-Lox) and expression of the oncogenic protein.
21 In
contrast to the H-Ras
Q61L mice, no phenotypic abnormalities
were observed in the urothelium of UroIICRE
þK-Ras
G12D
mice. There was little upregulation of pERK1/2 and pMEK1/2
and no upregulation of members of the PI3K-pAKT-p-mTOR
pathway (Supplementary Figure 3). There was no evidence of
increased Wnt signalling in these urothelium, that is, no
nuclear b-catenin or accumulation of Wnt targets such as
Sox9 (Supplementary Figure 3).
Ras activation cooperates with b-catenin to drive UCC
formation. We have previously demonstrated that
UroIICRE
þb-catenin
exon3/exon3 mice develop areas of
hyperproliferation in their urothelium from 3 months of ages
(increased levels of Ki-67 and BrdU incorporation), but these
lesions do not progress when these mice are aged up to 18
months. These lesions have high levels of the tumour-
suppressor p21 and PTEN, suggesting that further mutations
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that adding a second mutation (through genetic deletion of
PTEN) to these lesions was sufﬁcient to progress it to frank
carcinoma.
14
Given that our human data suggested a correlation
between upregulated Wnt signalling and MAPK pathway
activation, and that neither single mutant murine model
develops UCC,
14 we decided to test the cooperation of
b-catenin and Ras activation in vivo by generating the
UroIICRE
þb-catenin
exon3/exon3H-Ras
Q61L (n¼29) cohort.
Two experiments were performed, with mice either being
killed at 3 months of age or aged until tumour development.
In contrast to the singly mutant mice, the UroIICRE
þ
b-catenin
exon3/exon3H-Ras
Q61L (mean survival 231 days, med-
ian 236 days) mice rapidly developed symptoms of bladder
tumourigenesis, namely abdominal swelling, haematuria
(blood in the urine) and hunching (Figure 3j). On necropsy,
we observed bladder tumours with histological progression to
non-invasive papillary carcinomas were observed. We found
no evidence of metastasis in any of our models.
Tumours demonstrated upregulation of the proliferation
marker Ki-67 (Figure 3b), with the number of proliferating
cells within each tumour being much higher than in
the UroIICRE
þb-catenin
exon3/exon3 mice (Supplementary
Figure 4). This may possibly explain why lesions do not
progress in the single mutant. We observed signiﬁcant
upregulation of pERK1/2 and pMEK1/2 (Figures 3d and e,
Supplementary Figure 5), as well as upregulation of nuclear
b-catenin and the Wnt target genes such as Sox9 (Figures 3f
and g, Supplementary Figure 5). These tumours demon-
strated negligible levels of pAKT and an intact PTEN signal
(Figures 3h and i). This in contrast to our previous study
where we deleted PTEN in combination with b-catenin
activation and tumours have upregulation of p-AKT/p-mTOR
and were dependent on mTOR signalling.
14 Given the high
levels of proliferation within the tumours, we next examined
the expression of p21 within the tumours as this is high in
premalignant lesions in b-catenin mice and the H-Ras mice
alone (Figure 3c). Quantiﬁcation of p21 levels showed a
signiﬁcant reduction in positivity in the tumours compared
β-catenin
Figure 1 Correlation between b-catenin and pERK1/2 in human bladder UCC TMA. IHC of benign and UCC bladder samples revealing no b-catenin, pERK1/2 or p21
expression (a–c). In the UCC samples there was expression of nuclear b-catenin (d) corresponding upregulation of pERK1/2 (b), with scattered expression of p21 (c).
Scatterplot demonstrating correlation between b-catenin and pERK1/2 (d). Each core size is 1.5mm
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(Supplementary Figure 6, P-value 40.04, Mann–Whitney) and
premalignant lesions from mice where b-catenin is activated
alone within the bladder. Again, there was no nuclear
accumulation of p53 in these tumours (data not shown).
To assess whether there was a correlation in human UCC
between the loss of p21 and high levels of MAPK pathway,
we stained our UCC tissue microarrays (TMAs) for p21 levels
and correlated these levels with p-ERK1/2. The presence
of nuclear p21 was observed in a third of the tumour samples
(20 out of 60), and there was a signiﬁcant correlation
between upregulation of pERK1/2 and low levels of p21
(Pearson correlation coefﬁcient¼0.369, P¼0.005).
b-Catenin
exon3/exon3H-Ras
Q61L UCCs are highly
responsive to MEK inhibition. Our hypothesis was that
the UroIICRE
þb-catenin
exon3/exon3H-Ras
Q61L tumours were
driven by MAPK, given the elevated levels of pMEK1/2 and
pERK1/2 and not PI3K (low levels of pAKT) (Figure 4a). This
is converse to our UroIICRE
þb-catenin
exon3/exon3Pten
ﬂ/ﬂ
mouse tumours that we have previously demonstrated are
dependent on PI3K and mTOR signalling (and not MAPK)
(Figure 4a).
14 Thus, to test whether MAPK signalling
was driving our mutant Ras bladder tumours we treated
12-month-old UroIICRE
þb-catenin
exon3/exon3H-Ras
Q61L mice
that had palpable tumours and haematuria with PD184352,
MEK1/2 inhibitor, (n¼3) or vehicle (n¼3). We also treated
our UroIICRE
þb-catenin
exon3/exon3Pten
ﬂ/ﬂ mice, which we
have shown previously, are dependent on mTOR signalling
with this same regime. A signiﬁcant regression of
tumour bulk between the vehicle and MEK inhibitor treated
UroIICRE
þb-catenin
exon3/exon3H-Ras
Q61L mice was obser-
ved (Figure 4b). IHC for BrdU revealed a reduction in
proliferation in PD184352 treated tumours compared with
vehicle treatment (Figure 4c, Po0.05, Mann–Whitney test).
Quantiﬁcation of pMEK1/2 and pERK1/2 immunostaining
revealed reduction in the protein levels in the UroIICRE
þ
b-catenin
exon3/exon3H-Ras
Q61L tumours following MEK inhi-
bition (Figures 4d and e). Interestingly, the UroIICRE
þ
b-catenin
exon3/exon3Pten
ﬂ/ﬂ tumours, which respond to
Rapamycin, did not respond to the MEK inhibition, with no
signiﬁcant change in tumour size or proliferation.
Taken together, these data suggest UroIICRE
þb-cateni-
n
exon3/exon3H-Ras
Q61L tumours are sensitive to MEK inhi-
bition because of their dependence on the MAPK signalling
pathway.
p21 upregulation blocks b-catenin driven UCC. Given
this downregulation of p21 in tumours compared with high
levels of p21 in the single mutant H-Ras and b-catenin
activated bladders, we next wished to test the functional
importance. To do this, we intercrossed p21 knockout mice to
the b-catenin exon3 mice and asked if this now facilitated
tumour progression. The reason for choosing to cross to p21
knockout mice to the b-catenin
exon3/exon3 mice was that p21
was upregulated in nearly every cell of the early lesions so
could be acting as a tumour suppressor in this instance.
Thus, we generated the following cohorts: UroIICRE
þp21
 / 
and UroIICRE
þb-catenin
exon3/exon3p21
 /  (n¼6 and 16,
respectively). We then aged mice until tumour
development. The UroIICRE
þb-catenin
exon3/exon3p21
 / 
mice rapidly developed urothelial tumours (mean 237,
median 238 days). In comparison, UroIICRE
þp21
 /  mice
did not develop tumours and had no urothelial pheno-
type (Figure 5g). Tumours from the UroIICRE
þ
b-catenin
exon3/exon3p21
 /  mice demonstrated evidence of
proliferation by Ki-67 staining as well as high levels of nuclear
b-catenin and pERK1/2 (Figures 5a–d). As expected, the
lesions did not express p21 (or p53) (Figures 5e–f). This
suggests that p21 has a role in suppressing b-catenin
induced UCC.
Finally,to assessif this cooperationwas restrictedto H-Ras
mutation, we generated a cohort UroIICRE
þb-catenin
exon3/
exon3K-Ras
G12D (n¼25).In contrast tothe singlymutant mice,
the UroIICRE
þb-catenin
exon3/exon3K-Ras
G12D (mean survival
185 days, median 200 days) mice pheno-copied the
Figure 2 Histology from 12-month-old H-Ras
Q61L mice reveal activation of the
MAPK signalling pathway. The H-Ras
Q61L urothelium is hyperplastic in comparison
withthewild-typeurothelium(aandb).Therewasminimalproliferationasobserved
by Ki67 staining in wild-type and mutant mice (c and d). We noticed signiﬁcant
upregulation of the MAPK pathway members: pERK1/2 (e and f) and pMEK1/2
(g and h), as well as p21 (i and j) in the mutant mice compared with wild type
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þb-catenin
exon3/exon3H-Ras
Q61L mice, rapidly de-
velops symptoms of bladder tumourigenesis (Supplementary
Figure 7). Thus, this shows activation of Wnt signalling will
cooperate with either H-Ras or K-Ras mutation.
Discussion
Although UCC can be classiﬁed in two major subtypes
(superﬁcial and invasive), with H-Ras and FGRF3 mutations
being associated with superﬁcial cancer and RB and p53
mutation been associated with invasive cancers, very little is
known how these pathways drive bladder carcinogenesis
in vivo. It was thus of some surprise that H-Ras mutation was
not sufﬁcient to drive bladder carcinogenesis in the mouse
unless overexpressed. In a similar scenario, we have data to
suggest that FGFR3 mutation is not sufﬁcient to drive bladder
carcinogenesis in the mouse (Ahmad, unpublished data).
Moreover, it has recently been shown that PTEN and p53
only drive bladder tumourigenesis when combined.
22
The high propensity for bladder carcinogenesis in humans
may thus reﬂect the relatively low turnover of the bladder
epithelium (in comparison with the intestinal epithelium)
and the exposure of the bladder epithelium to carcinogens,
which allow multiple mutations to occur which provokes
tumourigenesis. It is thus critical to identify these other
signalling pathways that cooperate with these presumably
initiating mutations to drive cancer.
In this study, we show that deregulation of Wnt signalling
strongly cooperates with the activation of Ras to drive
tumourigenesis. First, we are able to demonstrate a correla-
tion between upregulation of b-catenin and pERK1/2 in our
TMA. Unfortunately there was no segregation into UCC
subtype, limiting our ability to predict whether this activation
occursinsuperﬁcial papillaryand/or muscle-invasivedisease.
We are currently addressing this concern by expanding
our human cohort. As our murine tumours are not invasive,
it would suggest that human tumour would develop via the
non-invasive/papillary UCC pathway; however, other muta-
tions could then occur to drive invasive UCC.
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Figure 3 UroIICRE
þ b-catenin
exon3/exon3 H-Ras
Q61L bladder tumours demonstrate upregulation of the MAPK and Wnt signalling pathways. These tumours demonstrate
upregulation of Ki-67 (b), minimal p21 staining (c) and upregulation of pERK1/2, pMEK1/2, b-catenin, and Sox9 (d–g). Also we notice no upregulation of pAKT (h) and
an intact PTEN signal (i). Black bar measures 200mm( 20 magniﬁcation). Kaplan–Meier curves of tumour-free survival of respective mutant cohorts (j). WT (wild type),
H-Ras (H-Ras
Q61L) and b-catenin H-Ras (UroIICRE
þb-catenin
exon3/exon3H-Ras
Q61L). Note the black (WT) and the red line (H-Ras) overlap one another
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Figure 4 MAPK, but not PI3K signalling is upregulated in UroIICRE
þ b-catenin
exon3/exon3 H-Ras
Q61L bladder tumours. Immunoblotting demonstrates upregulation of
pMEK1/2 and pERK1/2 in the UroIICRE
þb-catenin
exon3/exon3H-Ras
Q61L tumours, but not pAKT, which is upregulated in the UroIICRE
þb-catenin
exon3/exon3Pten
ﬂ/ﬂ
(but not pMEK1/2 or pERK1/2). We demonstrate that MEK inhibition can regress the UroIICRE
þb-catenin
exon3/exon3H-Ras
Q61L tumours in terms of size and proliferation
(b–c)( Po0.05, Mann–Whitney).We see no difference in the UroIICRE
þb-catenin
exon3/exon3Pten
ﬂ/ﬂ tumour size nor proliferation after MEK inhibition (b–c). We also notice a
reduction in pERK1/2 and pMEK1/2 protein levels on IHC in the UroIICRE
þb-catenin
exon3/exon3H-Ras
Q61L tumours (d–e)( Po0.05, Mann–Whitney). Ub H-Ras
Q61L
(UroIICRE
þb-catenin
exon3/exon3H-Ras
Q61L) and Ub Pten
ﬂ/ﬂ (UroIICRE
þb-catenin
exon3/exon3Pten
ﬂ/ﬂ)
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Figure 5 Histology of UroIICRE
þ b-catenin
exon3/exon3p21
 / mouse. H&E reveals bladder tumour (a) with upregulation of Ki67, b-catenin and pERK1/2 (b–d). There is
minimal upregulation of p53 and p21 (e and f). Black bar measures 200mm (20  magniﬁcation). Kaplan–Meier curves of tumour-free survival of UroIICRE
þp21
 /  and
UroIICRE
þb-catenin
exon3/exon3p21
 /  cohorts (g). p21 (UroIICRE
þp21
 / ) and Bcatenin p21 (UroIICRE
þb-catenin
exon3/exon3p21
 / )
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in this study are different in respect to knock-in/overexpres-
sion status. We utilised Lox-Stop-Lox K-Ras conditional
mouse strain, in which expression of oncogenic K-Ras
G12D
is controlled by a removable transcriptional termination
Stop element.
21 As the endogenous K-Ras locus is targeted
in the K-Ras
G12D strain, only endogenous levels of oncogenic
K-Ras
G12D are expressed (not overexpression). In contrast,
the H-Ras model is an overexpression of the oncogenic
rabbit transgene (point mutation at codon 61 of the second
exon converting CAG (encoding glutamine) to CTG
(leucine).
9 Transgene copy number varied from two copies
(low copy, UCC from 10 to 26 months of age) to 48 copies
(high copy, UCC from 4 months of age). This may account
for the difference in phenotypes of the Ras mutations
alone, namely no phenotype in the UroIICRE
þK-Ras
G12D
andpronouncedhyperplasiaintheoverexpressionH-Ras
Q61L
model. However, it is difﬁcult to make any deﬁnitive conclu-
sions because we are dealing with different Ras alleles.
In anticipation we are currently repeating these experiments
with a Lox-Stop-Lox H-Ras
G12V conditional mouse strain,
which will allow us to make direct comparisons. However,
despite these differences in the Ras protein (H-Ras
Q61L
or K-Ras
G12D) and the levels of expression of the mutant,
the cooperation of the either K-Ras or H-Ras mutations
were comparable. This suggests that increasing levels of
MAPK signalling in the context of activating Wnt signalling
will drive bladder carcinogenesis. This was further
conﬁrmed by tumour regression after inhibition of the MAPK
signalling cascade.
Interestingly, despite modelling all these mutations in the
murine urothelium, these tumours remain non-invasive and
do not metastasis despite extended follow-up. This is
consistent with tumours that have H-Ras mutations in
humans. These tend to remain superﬁcial and despite
recurrence rarely progress to metastasis. Therefore, the
model presented here still reﬂects a useful model of human
disease for preclinical testing. It is interesting to note the
tumours that develop following H-Ras mutation and b-catenin
activation have increased MAPK signalling (although not
p-AKT/p-mTOR activation), while tumours that have PTEN
loss and b-catenin activation show little MAPK pathway and
instead have high levels of p-AKT/p-MTOR.
14 We show that
as a result these tumours have differential sensitivity to MEK
and mTOR inhibition. As a result these models may be
relevant for human tumourigenesis as we show that there is a
subset of patients that have a correlation between high
b-catenin and high p-AKT and this group is distinct from those
patients that show high levels of p-ERK and b-catenin.
14
Moreover, given neither PTEN nor H-Ras mutation alone
leads to PI3 kinase or MAPK pathway activation respectively
invivo,itarguesinthebladderstrongfeedbacklooppathways
exist so deregulated signalling is not instigated. Thus,
activation of Wnt signalling in this case is cooperating to drive
either MAPK or PI3 kinase pathway activation depending on
the cooperating mutation. To this end, it is interesting to note
previous studies have linked Wnt pathway activation to
increase MAPK signalling.
23,24 Moreover, this may also help
to explain why multiple mutations are required to drive cancer
within the murine bladder.
Given the milieu of the bladder, other mutations may occur
in the recurrent tumours that may then drive metastasis. It is
likelythatthesemaybeinthep53tumoursuppressorasthese
mutations are common in metastatic bladder cancers and
co-deletionofPTENandp53ledtometastaticbladdercancer.
The precise mechanism for this is unclear, in many cancers
genomic instability is associated with metastasis although it is
still unclear how functionally important this is. A number of
groups (including our own) have shown that may also be
dominant gain of function properties to p53 mutations that
may also drive metastasis in vivo.
25,26
Mechanistically, it appears that p21 may block tumour
progression within the bladder. In our study, we show
p21 activation in both UroIICRE
þb-catenin
exon3/exon3 and
H-Ras
Q61L bladders and this is associated with failed to
progression to cancer. We have recently shown in a model of
pancreatic cancer that p21 loss accelerates tumourigenesis
following K-Ras
G12D mutation and identiﬁes a subset of a
patient with poor prognosis.
27 Thus, in both scenarios we
show that p21 can functionally block tumourigenesis and is
downregulated in human patients. Given the upregulation of
p21 in H-Ras
Q61L bladders, further studies intercrossing p21
knockout mice to these H-Ras
Q61L transgenic mice should be
performed and are currently underway in the laboratory. As
yet it is unclear the precise mechanism of p21 downregulation
in vivo as it is rarely mutated though mutation or down-
regulation of upstream factors such as p53 or Lkb1 could
account for a downregulation of this pathway. Our working
hypothesis is that in bladder cancer, p21 induction would
be observed early in precursor lesions (CIS) and low-grade
tumours, while the more aggressive and muscle-invasive
tumours will show loss of p21 and thus there may be
multiple ways to obtain p21 downregulation during bladder
carcinogenesis.
In summary, we have functionally the tested the ability of
Ras and Wnt pathway to cooperate to drive bladder
carcinogenesis and ﬁnd that they robustly cooperate to
promote non-metastatic bladder tumours. Given there is a
subset of human patients that show high levels of p-ERK and
b-catenin, it suggest that combinatorial targeting of the MAPK
and Wnt pathways may be efﬁcacious in these patients.
Subjects and Methods
Mice. Uroplakin II Cre mouse (UroIICRE
þ)
28 were intercrossed with mice
harbouring, b-catenin
exon3/þ, K-Ras
G12D, H-Ras
Q61L and p21
þ/  in combinations
as described below.
9,21,28–30 Mice were genotyped by PCR as previously
described.
9,21,28–30 Mice were of a mixed background and littermates were used
as controls. All experiments were carried out in accordance with UK animal
regulations.
When bladders were excised they were all emptied of urine, before being placed
in formalin for overnight ﬁxation before parafﬁn embedding. All bladders were
processed and cut in the same manner by a single histology technician to all
standardisation.
Immunohistochemistry. IHC was performed on formalin ﬁxed, parafﬁn-
embedded samples. For each genotype, we stained at least three samples from
different mice and took representative images for this paper. We used antibodies
against:Ki-67(VP-RM04,VectorLabs(Burlingame,CA,USA),1:100,citratebuffer
and water bath antigen retrieval – 50min at 991C), PTEN (#9559, Cell Signaling
(Danvers, MA,USA), 1:100, citratebufferand waterbath antigenretrieval– 50min
at 991C), pAKT(Ser473)(#3787,CellSignaling,1:50,citratebufferandmicrowave
antigen retrieval), b-catenin (C19220, Transduction Labs (Franklin Lakes, NJ, USA),
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Cell Death and Disease1:50, Tris/EDTA water bath antigen retrieval – 50min at 991C), p21 (M19, Santa
Cruz(SantaCruz,CA,USA),1:500,citratebufferandwaterbathantigenretrieval–
50min at 991C), p53 (VP-P956, Vector Labs, 1:200, citrate buffer and microwave
antigen retrieval), p-mTOR(Ser2448) (#2976, Cell Signaling, 1:100, citrate buffer
and microwave antigen retrieval), p-S6 Kinase(Thr421/Ser424) (#9204, Cell
Signaling, 1:100, citrate buffer and microwave antigen retrieval), Sox9 (AB5535
Chemicon (now part of Millipore, Billerica, MA, USA), 1:500, citrate buffer and
microwave antigen retrieval), p-Gsk3b(Ser 9) (#9336 Cell Signaling, 1:50, citrate
buffer and microwave antigen retrieval), pMEK1/2 (#2338 Cell Signaling, 1:125,
citrate buffer and microwave antigen retrieval) and pERK1/2 (#9101 Cell Signaling,
1:100, citrate buffer and microwave antigen retrieval).
Microscopy. Light microscopy was carried out using the Olympus BX51
(Olympus, Center Valley, PA, USA). For GFP in vivo imaging we used the Olympus
OV100 system. We imaged mice post-mortem with both skin intact and removed.
Human TMA. This was purchased from Folio Biosciences and consists of 60
UCCs and 20 benign bladder cores with data that consisted of patient sex, age and
tumour grade. Slides were scanned using the Aperio slide scanner (Aperio, Vista,
CA, USA).
Histoscore. Protein expression levels were scored by two independent
observers, blinded to the mouse genotype, using a weighted histoscore method,
also known as the H-score, at magniﬁcation  40 (IA and LBS).
14,31 An interclass
correlation coefﬁcient of 40.85 between the two scorers was achieved in all cases
before formal analysis. Each cellular location (membranes, cytoplasm and nuclei)
was scored separately. The weighted histoscore method assesses the staining
intensity and the percentage of cells stained with that intensity for the full slide. It is
calculated by (1 % cells staining weakly positive)þ(2 % cells staining
moderatelypositive)þ(3 %cellsstainingstronglypositive).Thisprovidesasemi-
quantitative classiﬁcation of staining intensity, with the maximum score being 300
(if 100% of cells stain strongly positive) and minimum score being 0
(if 100% or cells are negative). The weighted histoscore method is a well-
established method for scoring tissue that has heterogeneous staining.
MEK inhibitor treatment. PD184352 (Selleck Chemicals LLC, Houston, TX,
USA) or vehicle treatment was provided twice daily via intraperitoneal (i.p.) at
200mg/kg/dayfor7days.Thei.p.solutionwasmade10mg/mlin10%DMSO,10%
Cremophor (Sigma, St. Louis, MO, USA) and 80% water.
Immunoblotting. Tumours were homogenised in lysis buffer (50mM Tris pH
7.6, 150mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 1mM sodium
ortho-vanadate, 5mM sodium ﬂuoride and protease inhibitor cocktail, Calbiochem,
Darmstadt, Germany) using Precellys tissue homogeniser. Lysates were resolved
by SDS-PAGE on 4–12% gradient polyacrylamide gels (Invitrogen, Carlsbad, CA,
USA) at 200V for 1h and transferred electrophoretically onto PVDF membranes
(Milipore, Billerica, MA, USA) at 200mA for 1h. Blots were blocked for 30min with
5% skimmed milk, rinsed and probed with the respective antibodies (in 5% BSA,
0.1% Tween-20 containing TBS) overnight at 41C. After incubation with HRP-
conjugated secondary antibody, bands were detected using ECL (GE, Pittsburgh,
PA, USA) detection reagent. Immunoblotting was performed with the following
antibodies:p-AKTser473(CellSignaling9271),AKT(CellSignaling9272),p-mTOR
(Cell Signaling 2971), p-ERK (Cell Signaling 4377), ERK (Cell Signaling 4695),
p-MEK (Cell Signaling 2338) and MEK (Cell Signaling 4694).
Statistics. All statistics (Mann–Whitney, Pearson correlation coefﬁcient,
interclass correlation coefﬁcient, Cox regression analysis and Kaplan–Meier
survivalanalysis)wereperformedusingMinitab v15.For thecorrelations, a scoreof
Z100 was deﬁned as upregulation and o100 for downregulation as we have
published previously.
14 This was used because all the benign samples
demonstrated staining intensity o100 for b-catenin, pERK1/2 and p21.
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